IP Library Granted Patent US 8,053,454
Granted Patent B2
US 8,053,454 · App. 12/088,474 · Granted Nov 8, 2011

Pyridopyrimidinone inhibitors of PIM-1 and/or PIM-3

Assignee: Exelixis, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,053,454
App. No.
12/088,474
Granted
Nov 8, 2011
Kind
B2
Abstract

Compounds of formula (I), useful for inhibiting PIM-I and/or PIM-3: and pharmaceutically acceptable salts thereof, wherein Y, Z, R 1 , R 3 , Q, X and R 4 are as defined above. Pharmaceutical compositions and methods of treating diseases and conditions, such as cancer, are also disclosed.

Claims (96)

1. A compound according to formula I

or pharmaceutically acceptable salts thereof, wherein

Q is tetrazolyl;

X is —C(O)—;

R 1 is a halogen;

R 2 and R 5 are independently H or halogen;

R 3 is H, chloro, bromo, methyl, NR 6 R 7 , or methoxy;

R 4 is C 1 -C 7 alkyl, which is optionally substituted with C 2 -C 4 alkenyl, C 1 -C 4 alkoxy, NR 6 R 7 , —C 0 -C 6 alkylC(O)OR 6 , —O-phenyl where the phenyl is optionally substituted with 1, 2, or 3 groups that are independently, halogen, C 1 -C 4 alkyl, C 1 -C 4 alkoxy, hydroxyl, 4-methylpiperazin-1-yl, CF 3 , or OCF 3 .

R 6 and R 7 at each occurrence are independently H, C 1 -C 4 alkyl, C 2 -C 4 alkanoyl, or phenylC 1 -C 4 alkyl;

Y is CR 5 ; and

Z is CR 2 .

2. A compound according to formula I

or pharmaceutically acceptable salts thereof, wherein

Q is tetrazolyl;

X is —C(O)—;

R 1 is a halogen;

R 2 and R 5 are independently H or halogen;

R 3 is H, chloro, bromo, methyl, NR 6 R 7 , or methoxy;

R 4 is heteroaryl or heteroaryl C 1 -C 6 alkyl, each of which is optionally substituted with one or more groups, where each group is independently C 1 -C 6 alkyl, C 1 -C 6 alkoxy, halogen, —SO 2 —(C 1 -C 4 alkyl), —S—(C 1 -C 4 alkyl), C 1 -C 6 haloalkyl, C 1 -C 6 haloalkoxy, C 1 -C 6 alkoxy C 1 -C 6 alkyl, NR 6 R 7 , C 2 -C 6 alkanoyl, aryl, or C 1 -C 6 alkyl substituted with C 1 -C 6 alkoxycarbonyl, where the aryl is selected from phenyl and naphthyl, and where the aryl is optionally substituted with one or more groups, where each group is independently halogen, C 1 -C 6 haloalkyl, C 1 -C 6 haloalkoxy, C 1 -C 6 alkyl, C 1 -C 6 alkoxy, or hydroxy;

R 6 and R 7 at each occurrence are independently H, C 1 -C 4 alkyl, C 2 -C 4 alkanoyl, or phenylC 1 -C 4 alkyl;

Y is CR 5 ; and

Z is CR 2 .

3. A compound according to claim 2 , wherein

R 4 is heteroaryl or heteroaryl C 1 -C 6 alkyl, where the heteroaryl group is thienyl, thiadiazolyl, oxazolyl, benzothienyl, isoxazolyl, benzofuranyl, pyridyl, pyrazolyl, or furanyl, each of which is optionally substituted with one or more groups, where each group is independently halogen, C 1 -C 4 alkyl, —SO 2 —(C 1 -C 4 alkyl), —S—(C 1 -C 4 alkyl), C 1 -C 4 alkoxy, or aryl, where the aryl is phenyl optionally substituted with one or more groups, where each group is independently halogen, C 1 -C 4 haloalkyl, C 1 -C 4 haloalkoxy, C 1 -C 4 alkyl, C 1 -C 4 alkoxy, or hydroxy.

4. A compound according formula I

or pharmaceutically acceptable salts thereof, wherein

Q is tetrazolyl;

X is —C(O)—;

R 1 is a halogen;

R 2 and R 5 are independently H or halogen;

R 3 is H, chloro, bromo, methyl, NR 6 R 7 , or methoxy;

R 4 is heterocycloalkyl or heterocycloalkyl C 1 -C 6 alkyl, each of which is optionally substituted with one or more groups, where each group is independently C 1 -C 6 alkyl, C 1 -C 6 alkoxy, halogen, C 1 -C 6 haloalkyl, C 1 -C 6 haloalkoxy, C 1 -C 6 alkoxy C 1 -C 6 alkyl, NR 6 R 7 , C 2 -C 6 alkanoyl, aryl, or C 1 -C 6 alkyl substituted with C 1 -C 6 alkoxycarbonyl, where the aryl is selected from phenyl and naphthyl, and where the aryl is optionally substituted with one or more groups, where each group is that are independently halogen, C 1 -C 6 alkyl, C 1 -C 6 alkoxy, or hydroxy;

R 6 and R 7 at each occurrence are independently H, C 1 -C 4 alkyl, C 2 -C 4 alkanoyl, or phenylC 1 -C 4 alkyl;

Y is CR 5 ; and

Z is CR 2 .

5. A compound according to claim 4 , wherein

R 4 is heterocycloalkyl or heterocycloalkyl C 1 -C 6 alkyl, where the heterocycloalkyl group is 3-oxo-2-oxabicyclo[2.2.1]heptanyl, piperidinyl, or tetrahydrofuranyl, each of which is optionally substituted with one or more groups, where each group is independently C 1 -C 6 alkyl, C 1 -C 6 alkoxy, halogen, C 1 -C 4 haloalkyl, C 1 -C 4 haloalkoxy, C 1 -C 6 alkoxy C 1 -C 6 alkyl, NR 6 R 7 , C 2 -C 6 alkanoyl, aryl, or C 1 -C 6 alkyl substituted with C 1 -C 6 alkoxycarbonyl, the aryl is selected from phenyl and naphthyl, where the aryl is optionally substituted with one or more groups, where each group is independently halogen, C 1 -C 6 alkyl, C 1 -C 6 alkoxy, or hydroxy.

6. A compound according to claim 5 , wherein

R 4 is heterocycloalkyl or heterocycloalkyl C 1 -C 6 alkyl, where the heterocycloalkyl group is 3-oxo-2-oxabicyclo[2.2.1]heptane substituted with one or more methyl groups, piperidinyl substituted with C 2 -C 4 alkanoyl, or tetrahydrofuranyl.

7. A compound selected from one of:

3-Chloro-N-(5-chloro-2-(1H-tetrazol-5-yl)phenyl)thiophene-2-carboxamide;

N-[5-Chloro-2-(1H-tetrazol-5-yl)phenyl]-2,2-dimethylpropanamide;

N-[5-Chloro-2-(1H-tetrazol-5-yl)phenyl]cyclohexanecarboxamide;

N-[5-Chloro-2-(1H-tetrazol-5-yl)phenyl]-2-methylpropanamide;

N-[5-Chloro-2-(1H-tetrazol-5-yl)phenyl]-2-methylbutanamide;

N-[5-Chloro-2-(1H-tetrazol-5-yl)phenyl]-4-methyl-1,2,3-thiadiazole-5-carboxamide;

N-[5-Chloro-2-(1H-tetrazol-5-yl)phenyl]-2-cyclopentylacetamide;

(4R)—N-[5-Chloro-2-(1H-tetrazol-5-yl)phenyl]-4,7,7-trimethyl-3-oxo-2-oxabicyclo[2.2.1]heptane-1-carboxamide;

N-[5-Chloro-2-(1H-tetrazol-5-yl)phenyl]-3-methylbutanamide;

N-[5-Chloro-2-(1H-tetrazol-5-yl)phenyl]-5-methylisoxazole-3-carboxamide;

N-[5-Chloro-2-(1H-tetrazol-5-yl)phenyl]-2-(2-thienyl)acetamide;

N-[5-Chloro-2-(1H-tetrazol-5-yl)phenyl]-2-methylpentanamide;

3-Chloro-N-[5-chloro-2-(1H-tetrazol-5-yl)phenyl]-1-benzothiophene-2-carboxamide;

N-[5-Chloro-2-(1H-tetrazol-5-yl)phenyl]pentanamide;

N-[5-Chloro-2-(1H-tetrazol-5-yl)phenyl]isoxazole-5-carboxamide;

(3s,5s,7s)-N-[5-Chloro-2-(1H-tetrazol-5-yl)phenyl]tricyclo[3.3.1.1˜3,7˜]decane-1-carboxamide;

N-[5-Chloro-2-(1H-tetrazol-5-yl)phenyl]-2-ethylbutanamide;

N-[5-Chloro-2-(1H-tetrazol-5-yl)phenyl]butanamide;

N-[5-Chloro-2-(1H-tetrazol-5-yl)phenyl]cyclopentanecarboxamide;

N-[5-Chloro-2-(1H-tetrazol-5-yl)phenyl]-3,5-dimethylisoxazole-4-carboxamide;

N-[5-Chloro-2-(1H-tetrazol-5-yl)phenyl]propanamide;

N-[5-Chloro-2-(1H-tetrazol-5-yl)phenyl]-1-benzothiophene-2-carboxamide;

N-[5-Chloro-2-(1H-tetrazol-5-yl)phenyl]-4-methylpentanamide;

N-[5-Chloro-2-(1H-tetrazol-5-yl)phenyl]-2-(methyloxy)acetamide;

N-[5-Chloro-2-(1H-tetrazol-5-yl)phenyl]-N˜2˜,N˜2˜-dimethylglycinamide;

Ethyl 3-{[5-chloro-2-(1H-tetrazol-5-yl)phenyl]amino}-3-oxopropanoate;

N-[5-Chloro-2-(1H-tetrazol-5-yl)phenyl]-5-methyl-3-phenylisoxazole-4-carboxamide;

N-[3-Chloro-2-(1H-tetrazol-5-yl)phenyl]thiophene-2-carboxamide;

N-[2-Chloro-6-(1H-tetrazol-5-yl)phenyl]thiophene-2-carboxamide;

N-[5-Chloro-2-(1H-tetrazol-5-yl)phenyl]-3-methyl-1-benzofuran-2-carboxamide;

N-{2-[(Phenylmethyl)amino]-5-(1H-tetrazol-5-yl)pyrimidin-4-yl}thiophene-2-carboxamide;

N-[6-(1H-Tetrazol-5-yl)-1H-benzimidazol-5-yl]thiophene-2-carboxamide;

N-[5-Chloro-2-(1H-tetrazol-5-yl)phenyl]-2-ethylhexanamide;

N-[5-Chloro-2-(1H-tetrazol-5-yl)phenyl]-2-(phenyloxy)acetamide;

Methyl 4-{[5-chloro-2-(1H-tetrazol-5-yl)phenyl]amino}-4-oxobutanoate;

(1R,2R)—N-[5-Chloro-2-(1H-tetrazol-5-yl)phenyl]-2-phenylcyclopropanecarboxamide;

3-(2-Chlorophenyl)-N-[5-chloro-2-(1H-tetrazol-5-yl)phenyl]-5-methylisoxazole-4-carboxamide;

2-Chloro-N-[5-chloro-2-(1H-tetrazol-5-yl)phenyl]pyridine-3-carboxamide;

N-[5-Chloro-2-(1H-tetrazol-5-yl)phenyl]-2-(methylthio)pyridine-3-carboxamide;

3-(2-Chloro-6-fluorophenyl)-N-[5-chloro-2-(1H-tetrazol-5-yl)phenyl]-5-methylisoxazole-4-carboxamide;

3-Chloro-N-[5-chloro-2-(1H-tetrazol-5-yl)phenyl]-4-(methylsulfonyl)thiophene-2-carboxamide;

N-[5-Chloro-2-(1H-tetrazol-5-yl)phenyl]-2,5-dimethylfuran-3-carboxamide;

N-[5-Chloro-2-(1H-tetrazol-5-yl)phenyl]pent-4-enamide;

N-[5-Chloro-2-(1H-tetrazol-5-yl)phenyl]cyclopropanecarboxamide;

5-Chloro-N-[5-chloro-2-(1H-tetrazol-5-yl)phenyl]-1-methyl-1H-pyrazole-4-carboxamide;

2-[(4-Chlorophenyl)oxy]-N-[5-chloro-2-(1H-tetrazol-5-yl)phenyl]acetamide;

2-[(3-Chlorophenyl)oxy]-N-[5-chloro-2-(1H-tetrazol-5-yl)phenyl]acetamide;

N-[5-Chloro-2-(1H-tetrazol-5-yl)phenyl]-2-{[3-(methyloxy)phenyl]oxy}acetamide;

N-[5-Chloro-2-(1H-tetrazol-5-yl)phenyl]-3-(phenyloxy)propanamide;

N-[5-Chloro-2-(1H-tetrazol-5-yl)phenyl]-3-[(4-fluorophenyl)oxy]propanamide;

N-[5-Chloro-2-(1H-tetrazol-5-yl)phenyl]cyclobutanecarboxamide; and

N-[5-Chloro-2-(1H-tetrazol-5-yl)phenyl]-2-{[2-(4-methylpiperazin-1-yl)phenyl]oxy}acetamide;

or a pharmaceutically acceptable salt thereof.

8. A pharmaceutical composition comprising a compound of claim 1 , or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier, excipient or solvent.

9. A pharmaceutical composition comprising a compound of claim 2 , or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier, excipient or solvent.

10. A pharmaceutical composition comprising a compound of claim 4 , or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier, excipient or solvent.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 6, 2008
From: KEARNEY, PATRICK; BROWN, S. DAVID; KOLTUN, ELENA S.
To: EXELIXIS, INC.
Reel/Frame 020908/0183 →
Continuity (2)
Provisional Application 60724171 · Oct 6, 2005
Related Publication 20090042918A1 · Feb 12, 2009